Little progress has been made on the treatment of advanced pancreatic ... cancer. The role for other anti-VEGF and EGF receptor inhibitors continues to be investigated. Not only new therapeutic ...

Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

This discovery points to a new way to tackle pancreatic cancer. If scientists can find a way to block CD9 or stop the cancer ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Dr. Rahul S. Shinde, assistant professor in Wistar’s Ellen and Ronald Caplan Cancer Center, researches potential new therapies for treatment-resistant cancers like pancreatic cancer. In this ...

At the beginning of 2024, the American Cancer Society predicted that 2,001,140 new cancer cases and 611,720 ... and reflecting on the discoveries and advances that have been made in the field ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

[39] AZM475271 is an orally bioavailable anilinoquinazoline inhibitor of c-Src that has been tested for pancreatic cancer ... Not only new therapeutic agents, but also the identification of ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...